~ Buy the XENOVIEW (xenon xe-129 hyperpolarized) Drug Profile, 2024 PDF Report in the Report Store ~

XENOVIEW Drug Patent Profile

When do Xenoview patents expire, and when can generic versions of Xenoview launch?

Xenoview is a drug marketed by Polarean and is included in one NDA. There are two patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in XENOVIEW is xenon xe-129 hyperpolarized. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the xenon xe-129 hyperpolarized profile page.

DrugPatentWatch^® Generic Entry Outlook for Xenoview

Xenoview will be eligible for patent challenges on December 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XENOVIEW

International Patents:	6
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	9
Patent Applications:	81
What excipients (inactive ingredients) are in XENOVIEW?	XENOVIEW excipients list
DailyMed Link:	XENOVIEW at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XENOVIEW

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

214375

Dosage:

GAS;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XENOVIEW

XENOVIEW is protected by two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XENOVIEW

FDA Regulatory Exclusivity protecting XENOVIEW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Polarean	XENOVIEW	xenon xe-129 hyperpolarized	GAS;INHALATION	214375-001	Dec 23, 2022		RX	Yes	Yes			Y
Polarean	XENOVIEW	xenon xe-129 hyperpolarized	GAS;INHALATION	214375-001	Dec 23, 2022		RX	Yes	Yes			Y
Polarean	XENOVIEW	xenon xe-129 hyperpolarized	GAS;INHALATION	214375-001	Dec 23, 2022		RX	Yes	Yes

International Patents for XENOVIEW

See the table below for patents covering XENOVIEW around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015127208
Canada	2940109	SYSTEMES DE PRODUCTION DE GAZ NOBLES HYPERPOLARISES AVEC ELIMINATION, DETECTION ET/OU FILTRATION DE NANOAGREGATS ET PROCEDES ET DISPOSITIFS ASSOCIES (HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES)
Hungary	E045999
European Patent Office	3107583	SYSTÈMES DE PRODUCTION DE GAZ NOBLES HYPERPOLARISÉS AVEC ÉLIMINATION, DÉTECTION ET/OU FILTRATION DE NANOAGRÉGATS ET PROCÉDÉS ET DISPOSITIFS ASSOCIÉS (HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES)
China	106456808	具有纳米簇抑制、检测和/或过滤的超偏振稀有气体生产系统及相关的方法和装置 (Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices)
Australia	2015218883	Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices